Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Now a Phase 2 trial

posted on Feb 16, 2018 04:33PM

Before (11/19/2017): "A Phase 1b Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer"

After (2/8/2018): "A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer"

Current version here. Still listed as recruiting and estimated completion still listed as April 2018.

5 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply